RAI2

Summary

RAI2 (retinoic acid induced 2, HGNC:9835) is a protein-coding gene on chromosome Xp22.13, encoding Retinoic acid-induced protein 2 (Q9Y5P3).

Retinoic acid plays a critical role in development, cellular growth, and differentiation. The specific function of this retinoic acid-induced gene has not yet been determined but it may play a role in development. The chromosomal location of this gene designates it to be a candidate for diseases such as Nance-Horan syndrome, sensorineural deafness, non-specific X-linked cognitive disability, oral-facial-digital syndrome, and Fried syndrome. Alternate splicing results in multiple transcript variants.

Source: NCBI Gene 10742 — RefSeq curated summary.

At a glance

• Gene–disease (curated): congenital heart disease (Disputed, ClinGen)
• GWAS associations: 1
• Clinical variants (ClinVar): 128 total — 1 pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_021785

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9835
Approved symbol	RAI2
Name	retinoic acid induced 2
Location	Xp22.13
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000131831
Ensembl biotype	protein_coding
OMIM	300217
Entrez	10742

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 21 protein_coding

ENST00000331511, ENST00000360011, ENST00000415486, ENST00000451717, ENST00000509491, ENST00000545871, ENST00000871541, ENST00000871542, ENST00000871543, ENST00000871544, ENST00000871545, ENST00000871546, ENST00000871547, ENST00000871548, ENST00000871549, ENST00000871550, ENST00000951757, ENST00000951758, ENST00000951759, ENST00000951760, ENST00000951761

RefSeq mRNA: 4 — MANE Select: NM_021785 NM_001172732, NM_001172739, NM_001172743, NM_021785

CCDS: CCDS14183, CCDS55374

Canonical transcript exons

ENST00000451717 — 2 exons

Exon	Start	End
ENSE00003284064	17861098	17861298
ENSE00003849071	17800049	17802034

Expression profiles

Bgee: expression breadth ubiquitous, 260 present calls, max score 95.91.

FANTOM5 (CAGE): breadth broad, TPM avg 3.3628 / max 97.3259, expressed in 676 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
198584	2.1505	564
198582	0.6505	271
198583	0.4516	233
198581	0.1102	52

Top tissues by expression

282 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left uterine tube	UBERON:0001303	95.91	gold quality
urethra	UBERON:0000057	95.37	gold quality
right lung	UBERON:0002167	94.93	gold quality
endocervix	UBERON:0000458	94.91	gold quality
body of uterus	UBERON:0009853	94.88	gold quality
saphenous vein	UBERON:0007318	94.56	gold quality
mucosa of stomach	UBERON:0001199	94.11	gold quality
left ovary	UBERON:0002119	93.64	gold quality
vena cava	UBERON:0004087	93.50	gold quality
decidua	UBERON:0002450	93.39	gold quality
myometrium	UBERON:0001296	93.18	gold quality
right ovary	UBERON:0002118	93.11	gold quality
ectocervix	UBERON:0012249	92.55	gold quality
lower lobe of lung	UBERON:0008949	92.49	gold quality
subcutaneous adipose tissue	UBERON:0002190	92.30	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	91.93	gold quality
lower esophagus muscularis layer	UBERON:0035833	91.79	gold quality
seminal vesicle	UBERON:0000998	91.74	gold quality
lower esophagus	UBERON:0013473	91.74	gold quality
cardia of stomach	UBERON:0001162	91.40	gold quality
right atrium auricular region	UBERON:0006631	91.40	gold quality
right uterine tube	UBERON:0001302	91.39	gold quality
peritoneum	UBERON:0002358	91.39	gold quality
omental fat pad	UBERON:0010414	91.38	gold quality
cardiac atrium	UBERON:0002081	91.27	gold quality
popliteal artery	UBERON:0002250	91.25	gold quality
tibial artery	UBERON:0007610	91.23	gold quality
adipose tissue of abdominal region	UBERON:0007808	91.22	gold quality
aorta	UBERON:0000947	91.03	gold quality
fundus of stomach	UBERON:0001160	90.93	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	13.72

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

66 targeting RAI2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-130B-3P	99.90	73.27	1850
HSA-MIR-301A-3P	99.90	73.15	1839
HSA-MIR-301B-3P	99.90	73.19	1836
HSA-MIR-3666	99.90	73.24	1833
HSA-MIR-4295	99.90	73.11	1838
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085

Literature-anchored findings (GeneRIF, showing 6)

• We specified the role of the RAI2 protein to function as a transcriptional regulator that controls the expression of several key regulators of breast epithelial integrity and cancer. (PMID:25716347)
• Here, we report a microdeletion of 170,6 Kb at Xp22.13 (17.733.948-17.904.576) (GRCh37/hg19).The microdeletion harbors the NHS, SCLML1, and RAI2 genes and results in a phenotype consistent with Nance-Horan syndromesyndrome and developmental delay. (PMID:28464487)
• RAI2 is frequently methylated in colorectal cancer, and its expression is regulated by promoter region methylation. Methylation of RAI2 is an independent prognostic marker of poor survival. RAI2 suppresses CRC cell growth both in vitro and in vivo. RAI2 induces cell apoptosis and suppresses CRC cell migration and invasion. RAI2 may serve as a tumor suppressor by inhibiting the AKT signaling pathway in CRC. (PMID:29796120)
• Low RAI2 expression is a marker of poor prognosis in breast cancer. (PMID:33782811)
• Expression Patterns and Corepressor Function of Retinoic Acid-induced 2 in Prostate Cancer. (PMID:35652463)
• EZH2 affects malignant progression and DNA damage repair of lung adenocarcinoma cells by regulating RAI2 expression. (PMID:35939884)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Rai2	ENSMUSG00000043518
rattus_norvegicus	Rai2	ENSRNOG00000006670
drosophila_melanogaster	Sobp	FBGN0033654

Paralogs (1): SOBP (ENSG00000112320)

Protein

Protein identifiers

Retinoic acid-induced protein 2 — Q9Y5P3 (reviewed: Q9Y5P3)

All UniProt accessions (2): Q9Y5P3, R4GNA9

Isoforms (2)

UniProt ID	Names	Canonical?
Q9Y5P3-1	1	yes
Q9Y5P3-2	2

RefSeq proteins (4): NP_001166203, NP_001166210, NP_001166214, NP_068557* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026092	RAI2/SOBP	Family

Pfam: PF15279

UniProt features (6 total): sequence variant 2, chain 1, region of interest 1, compositionally biased region 1, splice variant 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
8ATI	X-RAY DIFFRACTION	2.6
8ARI	ELECTRON MICROSCOPY	3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y5P3-F1	50.27	0.00

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 109 (showing top): GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, SRF_Q5_01, FINAK_BREAST_CANCER_SDPP_SIGNATURE, WCTCNATGGY_UNKNOWN, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP, GOBP_EMBRYO_DEVELOPMENT, VECCHI_GASTRIC_CANCER_EARLY_DN, LEE_AGING_MUSCLE_DN, RIGGINS_TAMOXIFEN_RESISTANCE_DN, TTTGCAC_MIR19A_MIR19B, TGGAAA_NFAT_Q4_01, MASSARWEH_TAMOXIFEN_RESISTANCE_UP, CAGCTTT_MIR320, BOQUEST_STEM_CELL_CULTURED_VS_FRESH_UP

GO Biological Process (2): embryo development ending in birth or egg hatching (GO:0009792), animal organ development (GO:0048513)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
embryo development	1
anatomical structure development	1
binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

896 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RAI2	NHS	Q6T4R5	952
RAI2	CDKL5	O76039	776
RAI2	GCNT2	Q8N0V5	553
RAI2	REPS2	Q8NFH8	512
RAI2	LMBRD2	Q68DH5	479
RAI2	SCML2	Q9UQR0	453
RAI2	DEPDC1B	Q8WUY9	449
RAI2	PALM2AKAP2	Q9Y2D5	411
RAI2	BEND2	Q8NDZ0	398
RAI2	TRIM3	O75382	393
RAI2	RWDD2A	Q9UIY3	390
RAI2	MEAK7	Q6P9B6	371
RAI2	TRIM41	Q8WV44	366
RAI2	CAPSL	Q8WWF8	365
RAI2	CDC42SE2	Q9NRR3	363

IntAct

71 interactions, top by confidence:

A	B	Type	Score
CTBP1	ZEB2	psi-mi:“MI:0914”(association)	0.800
RAI2	FHL2	psi-mi:“MI:0915”(physical association)	0.780
FHL2	RAI2	psi-mi:“MI:0915”(physical association)	0.780
SGTB	RAI2	psi-mi:“MI:0915”(physical association)	0.740
RAI2	SGTB	psi-mi:“MI:0915”(physical association)	0.740
CTBP2	RAI2	psi-mi:“MI:0915”(physical association)	0.670
RAI2	CTBP2	psi-mi:“MI:0915”(physical association)	0.670
CTBP1	RAI2	psi-mi:“MI:0915”(physical association)	0.590
CTBP2	RAI2	psi-mi:“MI:0915”(physical association)	0.560
RAI2	CTBP2	psi-mi:“MI:0915”(physical association)	0.560
UBQLN1	RAI2	psi-mi:“MI:0915”(physical association)	0.560
DR1	RAI2	psi-mi:“MI:0915”(physical association)	0.560
RAI2		psi-mi:“MI:0915”(physical association)	0.560
RAI2	HSPB1	psi-mi:“MI:0915”(physical association)	0.560
RAI2	NEFL	psi-mi:“MI:0915”(physical association)	0.560
RAI2	PRPS1	psi-mi:“MI:0915”(physical association)	0.560
RAI2	WFS1	psi-mi:“MI:0915”(physical association)	0.560
RAI2	GTF3C3	psi-mi:“MI:0915”(physical association)	0.560
RAI2	KIF1B	psi-mi:“MI:0915”(physical association)	0.560
RNF11	RAI2	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (31): RAI2 (Two-hybrid), RAI2 (Two-hybrid), SGTB (Two-hybrid), RAI2 (Two-hybrid), SGTB (Two-hybrid), RAI2 (Two-hybrid), RAI2 (Two-hybrid), RAI2 (Two-hybrid), RAI2 (Two-hybrid), UBQLN1 (Two-hybrid), RAI2 (Two-hybrid), RAI2 (Two-hybrid), RAI2 (Two-hybrid), CRYGS (Affinity Capture-MS), RNF114 (Affinity Capture-MS)

ESM2 similar proteins: A0JME2, A5D7F6, F8VPZ9, O88873, O89090, P08047, P31367, P52591, P54253, P58929, P70178, P78364, Q01714, Q02086, Q07916, Q08E26, Q13227, Q14863, Q2VPU4, Q3U182, Q5E9U0, Q64028, Q66JY2, Q6AI39, Q6T264, Q7Z3K3, Q8BLM0, Q8BZH4, Q8CHH5, Q8CHP6, Q8IXK0, Q8IZL2, Q8K3Z9, Q8K4J6, Q8N196, Q8N1G0, Q8NDX5, Q8QHL5, Q8VHG2, Q91VX2

Diamond homologs: A5X7A0, A7XYH5, A7XYH9, A7XYI6, A7XYJ6, A7XYQ1, Q0P5V2, Q9Y5P3, Q9QVY8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

128 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	74
Likely benign	6
Benign	5

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3024649	GRCh37/hg19 Xp22.2-22.13(chrX:16582625-18323335)x0	Pathogenic

SpliceAI

907 predictions. Top by Δscore:

Variant	Effect	Δscore
X:17802030:TTGGC:T	acceptor_gain	1.0000
X:17802031:TGGC:T	acceptor_gain	1.0000
X:17802032:GGC:G	acceptor_gain	1.0000
X:17802033:GC:G	acceptor_gain	1.0000
X:17802034:CC:C	acceptor_gain	1.0000
X:17802034:CCTGC:C	acceptor_loss	1.0000
X:17802035:C:CC	acceptor_gain	1.0000
X:17802036:T:C	acceptor_loss	1.0000
X:17860508:CCCGG:C	donor_gain	1.0000
X:17860583:TTCC:T	donor_gain	1.0000
X:17802039:A:T	acceptor_gain	0.9900
X:17802041:C:CT	acceptor_gain	0.9900
X:17802044:A:T	acceptor_gain	0.9900
X:17860503:ACTC:A	donor_loss	0.9900
X:17860504:CT:C	donor_loss	0.9900
X:17860505:TCA:T	donor_loss	0.9900
X:17860506:CACC:C	donor_loss	0.9900
X:17860507:A:AC	donor_gain	0.9900
X:17860507:AC:A	donor_gain	0.9900
X:17860508:C:CC	donor_gain	0.9900
X:17860508:C:CG	donor_loss	0.9900
X:17860508:CC:C	donor_gain	0.9900
X:17860582:TTTC:T	donor_gain	0.9900
X:17860584:T:A	donor_gain	0.9900
X:17802038:C:CT	acceptor_gain	0.9800
X:17802043:C:CT	acceptor_gain	0.9800
X:17844026:CAG:C	donor_gain	0.9800
X:17860580:A:C	donor_gain	0.9800
X:17860354:C:CA	donor_gain	0.9700
X:17802033:GCCT:G	acceptor_gain	0.9600

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000008884 (X:17808213 C>A), RS1000053265 (X:17811360 C>T), RS1000061171 (X:17823538 G>A), RS1000148792 (X:17824762 CT>C), RS1000277819 (X:17832296 C>A,T), RS1000308353 (X:17837933 G>A), RS1000401706 (X:17855930 A>C), RS1000470081 (X:17846562 C>T), RS1000470958 (X:17828422 C>T), RS1000553010 (X:17818681 G>A), RS1000668514 (X:17822510 T>A), RS1000889262 (X:17862225 A>C), RS1000912105 (X:17862866 G>A,C), RS1000977870 (X:17800013 A>G), RS1000984218 (X:17819010 C>G,T)

Disease associations

OMIM: gene MIM:300217 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
congenital heart disease	Disputed Evidence	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
congenital heart disease	Disputed	AD

Mondo (2): dextrocardia (MONDO:0015661), congenital heart disease (MONDO:0005453)

Orphanet (1): Dextrocardia (Orphanet:1666)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0001651	Dextrocardia

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST004093_3	Prostate-specific antigen levels	3.000000e-15

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D003914	Dextrocardia	C14.240.400.280; C14.280.400.280; C16.131.240.400.280; C16.131.810.250
D006330	Heart Defects, Congenital	C14.240.400; C14.280.400; C16.131.240.400

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression, increases methylation	7
bisphenol A	increases expression, affects cotreatment	2
Benzo(a)pyrene	affects methylation	2
Dexamethasone	increases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Silicon Dioxide	increases expression	2
Tetrachlorodibenzodioxin	increases expression, decreases expression	2
Tretinoin	decreases expression, increases expression	2
Cyclosporine	decreases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
p-Chloromercuribenzoic Acid	decreases expression, affects cotreatment	2
trichostatin A	increases expression	1
sodium arsenite	increases expression	1
butyraldehyde	increases expression	1
mercuric bromide	affects cotreatment, decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Resveratrol	decreases expression, affects cotreatment	1
Zoledronic Acid	increases expression	1
Acetaminophen	decreases expression	1
Calcitriol	increases expression, affects cotreatment	1
Copper	affects binding, decreases expression	1
Disulfiram	affects binding, decreases expression	1
Doxorubicin	decreases expression	1
Indomethacin	affects cotreatment, increases expression	1
Phthalic Acids	decreases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Testosterone	increases expression, affects cotreatment	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00668824	PHASE4	UNKNOWN	Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist
NCT01368705	PHASE4	COMPLETED	Nitrogen Balance in Infants After Post Cardiothoracic Surgery
NCT01619982	PHASE4	COMPLETED	Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients
NCT02122679	PHASE4	WITHDRAWN	Tranexamic Acid Effect on Platelet Aggregation Following Infant Cardiopulmonary Bypass
NCT02527811	PHASE4	UNKNOWN	Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery
NCT03014700	PHASE4	COMPLETED	Fibrinogen Concentrate vs Cryoprecipitate
NCT03408340	PHASE4	TERMINATED	Paravertebral Nerve Blocks in Neonates
NCT03630796	PHASE4	UNKNOWN	Effect of Sevoflurane in Postoperative Troponin I Levels in Children Undergoing Congenital Heart Defects Surgery
NCT03667703	PHASE4	COMPLETED	Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease
NCT04453761	PHASE4	UNKNOWN	Thiamine Influenced on Substrate Energy Effectiveness in Indonesian Children Undergoing Cardiopulmonary Bypass
NCT06668389	PHASE4	RECRUITING	Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial
NCT07499154	PHASE4	NOT_YET_RECRUITING	Perioperative Lidocaine for Lung Protection in Infants Undergoing Cardiac Surgery
NCT00000470	PHASE3	COMPLETED	Infant Heart Surgery: Central Nervous System Sequelae of Circulatory Arrest
NCT00000494	PHASE3	COMPLETED	Management of Patent Ductus in Premature Infants
NCT01134302	PHASE3	UNKNOWN	Hybrid Versus Norwood Management Strategies in Infants Undergoing Single Ventricle Palliation
NCT01607983	PHASE3	WITHDRAWN	Effects of Pulmonary Vasodilation Upon VA Coupling in Fontan Patients
NCT01662011	PHASE3	UNKNOWN	Application of Neurally Adjusted Ventilatory Assist to Children After Congenital Cardiac Surgery
NCT02320669	PHASE3	COMPLETED	Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
NCT02615262	PHASE3	COMPLETED	Intraoperative Dexamethasone in Pediatric Cardiac Surgery
NCT03153137	PHASE3	COMPLETED	Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects
NCT03154476	PHASE3	COMPLETED	Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study
NCT04536194	PHASE3	COMPLETED	Dopamine Versus Norepinephrine Under General Anesthesia
NCT04702373	PHASE3	ACTIVE_NOT_RECRUITING	Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT
NCT05049590	PHASE3	COMPLETED	Acute Normovolemic Hemodilution in Complex Cardiac Surgery
NCT06406517	PHASE3	UNKNOWN	Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics
NCT06693674	PHASE3	RECRUITING	Effect of Sacubitril-Valsartan on Cardiac Structure and Function
NCT06955260	PHASE3	NOT_YET_RECRUITING	SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
NCT00115375	PHASE2	COMPLETED	Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)
NCT00350220	PHASE2	COMPLETED	Transfusion Strategies in Pediatric Cardiothoracic Surgery
NCT00374088	PHASE2	COMPLETED	N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)
NCT00538785	PHASE2	COMPLETED	A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
NCT00770705	PHASE2	WITHDRAWN	Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery
NCT00919945	PHASE2	TERMINATED	Impact of Early Enteral Feeding on Splanchnic Blood Flow After Surgery for Critical Heart Disease in the Newborn
NCT01063712	PHASE2	COMPLETED	Safety and Effectiveness of the Device Nit-Occlud® PDA-R
NCT01069510	PHASE2	COMPLETED	Spironolactone in Adult Congenital Heart Disease
NCT01189981	PHASE2	COMPLETED	Effect of eHealth Encouragements to Intensive Exercise in Adolescents With Congenital Heart Disease
NCT01330433	PHASE2	COMPLETED	Effects of CoSeal on Bleeding & Adhesions in Pediatric Heart Surgery
NCT01662037	PHASE2	COMPLETED	Bosentan Therapy in Children With Functional Single Ventricle
NCT01668264	PHASE2	UNKNOWN	Imaging Assessment of Diastolic Function
NCT01827059	PHASE2	UNKNOWN	Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE